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Serum levels of interleukin-6 (IL-6) were determined in 97 patients with clinically diagnosed Alzheimer's 
disease and 79 age- and sex-matched control subjects. Median serum levels of IL-6 did not differ signifi- 
cantly between Alzheimer patients (8.6 U/ml) and controls (8.2 U/ml). Median levels of serum IL-6 were 
similar for sporadic and familial patients. The concentration of IL-6 was not associated with the severity 
of the dementia or the duration of the disease since first symptoms. According to these observations there 
is no evidence for a significant elevation in serum IL-6 in Alzheimer's disease. 
In patients with Alzheimer's disease, extracellular amyloid fibrils accumulate in the 
cores of the senile plaques and in cerebral and meningeal microvessels [8]. Two lines 
of evidence suggest hat the formation of amyloid deposits in Alzheimer's disease 
may be accompanied by an acute-phase response, the reaction of the body to tissue 
damage and inflammatory processes. First, the amyloid in the senile plaques has been 
demonstrated to be tightly associated with the acute-phase protein 71-antichymo- 
trypsin [1, 2]. Second, increased serum levels of the acute-phase proteins have been 
reported in patients with Alzheimer's disease [3, 7]. 
Recently, it has been demonstrated that the production of acute-phase proteins is 
at least in part mediated by two lymphokines, interleukin-1 (IL-1) and interleukin-6 
(IL-6) [5, 6, 15, 16, 17]. These lymphokines are produced by a variety of cells and 
have several functions inside and outside the immune system [17]. The increased se- 
rum levels of IL-6 that have been demonstrated in patients rejecting their kidney 
transplantant [20], patients with serious skin injury [16], and in patients with rheuma- 
toid arthritis [11, 21] indicate that inflammatory processes can be sensitively moni- 
tored by an IL-6 bio-assay. Therefore, we have used this assay to study serum levels 
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of IL-6, as a serologic marker of disease and severity of dementia in 97 patients with 
clinically diagnosed Alzheimer's disease, and in 79 population control subjects. 
Patients were derived from an epidemiological study of risk factors of clinically 
diagnosed Alzheimer's disease. For this study all early onset patients (diagnosis ~< 70 
years) living in the 4 northern provinces of the Netherlands in whom the diagnoses 
was made in the period of January 1980 to July 1987 were ascertained [10]. Demen- 
tia's other than Alzheimer's disease (e.g. multi-infarct dementia, and dementia 
secondary to alcoholism, depression, metabolic disorders, epilepsy, Parkinson's dis- 
ease, and other conditions) were excluded using a clinical history, neurological exa- 
mination, and neuropsychological and laboratory tests [14]. For this study the diag- 
nosis of Alzheimer's disease was confirmed independently. All patients fulfilled the 
following criteria: (1) slow progressive decline of intellectual function; (2) a score on 
the clinical dementia rating scale of more than 0.5 [12]; (3) a score on the short porta- 
ble mental status questionnaire (SPMSQ) of less than 20 [18]; (4) a score of 7 or less 
on the Hachinski-scale [9]; and (5) no evidence for abnormalities on CT-scan other 
than cerebral atrophy, and no evidence for focal dysfunction in the EEG. For each 
patient a control subject matched for age (within 5 year age groups) and gender was 
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Fig. 1. Measurement of IL-6 in serum. Several mounts of human recombinant IL-6 (0), serum from 
one patient with Alzheimer's disease (O), and serum from two controls (I-I and II) were compared with 
regard to their ability to induce proliferation byB9 cells. 
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selected from the municipal place of residence of the patients. None of the control 
subjects howed signs of dementia s measured by the SPMSQ. 127 patients and 127 
controls from the 4 Northern provinces participated in the initial study; serum sam- 
ples were available for 97 patients (76%) and 79 controls (62%). 
Serum levels of IL-6 were determined in stored serum samples (-80°C) with the 
use ofa bio-assay [16]. IL-6 dependent B9 hybridoma cells as well as human recombi- 
nant IL-6 were kindly provided by Dr. L. Aarden, Central Laboratory of the Blood 
Transfusion Service, Amsterdam. The cells were cultured in Iscoves' modified Dul- 
becco's medium (Seromed, Berlin, F.R.G.), supplemented with penicillin (100 U/ml), 
streptomycin (100/tg/ml), 2 mM L-glutamin, 5x 10 -5 M 2-mercapto-ethanol and 5% 
(v/v) foetal calf serum (Seralab, Crawley Down, U.K.). Sera from patients with Alz- 
heimer's disease and from control subjects were serially diluted in duplicate in the 
same medium in fiat-bottom microtiter plates (Greiner, Nfirtingen, F.R.G.). Five 
thousand B9 cells were added to each well and the final volume was adjusted to 200 
#1. After 66 h of culture, the cells were pulsed with 0.25 #Ci [3H]methyl-thymidine 
(spec. act. 2 CI/mmol; Radiochemical Center, Amersham, U.K.). Six hours later, the 
cultures were terminated by harvesting the DNA on nitrocellulose filters (Skatron, 
Tranby, Norway). Filters were counted in toluene, containing 4 g/l PPO and 0.05 g/l 
POPOP. One unit IL-6/ml was dettned as the concentration at which half-maximal 
proliferation was found; recombinant IL-6 served as a standard. 
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Fig. 2. Interleukin-6 (IL-6) in serum of Alzheimer patients and age- and sex-matched controls. 
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As appears from Fig. 1, the B9 assay is highly sensitive to IL-6. The B9 cells proli- 
ferated in a dose-dependent manner in response to rlL-6. The assay detected levels 
of rlL-6 as low as 0.1 U/ml. Maximal proliferation of the cells occurred in the pres- 
ence of approximately 5 U/ml. Parallel dose response curves were obtained when 
positive sera were diluted. These three individual sera numbered 1052, 2063 and 2082 
were found to contain 25, 96 and 650 U IL-6/ml, respectively. 
Median concentrations of serum IL-6 did not differ significantly (P < 0.40) between 
Alzheimer patients (8.6 U/ml, range: 4.6-34.0) and controls (8.4 U/ml, range: 
5.8-650.0). Five patients with Alzheimer's disease as well as 5 controls had a history 
of rheumatoid disease. In two subjects with rheumatoid arthritis increased IL-6 levels 
(94.0 U/ml and 650 U/ml) may have been due to the fact that these patients uffered 
from rheumatoid arthritis. Upon exclusion of all patients with rheumatoid arthritis 
median levels of serum IL-6 were 8.6 U/ml (range: 4.6-34.0) for patients with Alz- 
heimer's disease and 8.2 U/ml (range: 5.8-30.0) for the controls (Fig. 2). In 5% (4/74) 
of the controls the concentration f serum IL-6 was above 13.0 U/ml; serum levels 
over 13.0 U/ml were found in twice as many Alzheimer patients (11%=10/93; 
P< 0.17). Serum levels of IL-6 were similar for the 43 sporadic patients (those with 
no family history of dementia) and the 49 familial patients (those with one or more 
first degree relatives with dementia). Median levels of serum IL-6 were 8.6 U/ml 
(range: 4.6-34.0) for sporadic patients and 8.2 U/ml (range: 4.8-28.0) for familial 
patients (P< 0.42). High concentrations of IL-6 were not associated with the severity 
of the dementia measured by the clinical dementia rating scale or with the duration 
of the disease since the first symptoms. 
Earlier studies have reported increased serum levels of acute-phase proteins in 
patients with Alzheimer's disease [3, 7]. In the present study of well-defined patients 
with clinically diagnosed Alzheimer's disease we do not obtain evidence for elevated 
serum levels of IL-6, one of the mediators of the acute-phase r sponse, as compared 
to age- and sex-matched population controls. In some patients and controls elevated 
levels of IL-6 were found in serum. Since no obvious ymptoms accounted for these 
findings, it is likely that subclinical inflammatory processes were responsible. Our 
findings do not exclude of course the possibility that the concentration of IL-6 is 
locally elevated within the central nervous ystem. Recently an increased number of 
IL-1 positive cells have been reported in patients with Alzheimer's disease and 
Down's syndrome [13]. Support for a local synthesis of IL-6 is provided by observa- 
tions in mice [16]. It has been suggested that IL-6 may be involved in repair mecha- 
nisms by increasing the secretion of nerve growth factor by astrocytes [16]. Therefore, 
it is conceivable that IL-6 production, like IL-1, may be altered in Alzheimer's disease 
and further studies of levels of IL-6 within autopsy material will certainly be of inter- 
est. 
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